key: cord-0919117-oe8vwxz8
authors: Memel, Zoe N; Lee, Jenny J; Foulkes, Andrea S; Chung, Raymond T; Thaweethai, Tanayott; Bloom, Patricia P
title: Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection
date: 2021-10-19
journal: J Infect Dis
DOI: 10.1093/infdis/jiab539
sha: cb56cf5d976deb861baf7d340605303355ac6a67
doc_id: 919117
cord_uid: oe8vwxz8

BACKGROUND: Statins may be protective in SARS-CoV-2 infection. The aim of this study was to evaluate the effect of in-hospital statin use on 28-day mortality and ICU admission among patients with SARS-CoV-2 stratified into 4 groups: those who used statins prior to hospitalization (continued, discontinued) and those who did not (newly initiated, never). METHODS: In a cohort study of 1179 patients with SARS-CoV-2, chart review was used to assess demographics, laboratory measurements, comorbidities, and time from admission to death, ICU admission, or discharge. Using marginal structural Cox models, we estimated hazard ratios for mortality and ICU admission. RESULTS: Among 1179 patients, 676 (57 %) were male, 443 (37 %) were at least 65 years old, and 493 (46%) had a BMI ≥30. Inpatient statin use reduced the hazard of death (HR 0.566, P = 0.008). This association held among patients who did and did not use statins prior to hospitalization (HR 0.270, P=0.003; HR 0.493, P=0.038). Statin use was associated with improved time-to-death for patients >65 years, but not patients ≤65 years. CONCLUSION: Statin use during hospitalization for SARS-CoV-2 infection was associated with reduced 28-day mortality. Well-designed randomized control trials are needed to better define this relationship.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the associated disease has resulted in millions of deaths (1). During the initial rush for treatments, over 100 offlabel drugs were used to treat patients with COVID-19 (2) . Off-label statin use was considered early in the pandemic at Massachusetts General Hospital (MGH) for several reasons, including: reports of cardiac complications due to COVID-19 (3, 4) and the cardioprotective effect of statins (5, 6) ; statins are low cost and generally safe (7) ; and statins blunt the hyperinflammatory response from infection (8, 9) . It was also suggested that statins block SARS-CoV-2 infectivity via binding to the main protease mediating viral entry, inhibiting the virus' ability to invade cells (10) .

The safety and efficacy of statins for the treatment of patients hospitalized with COVID-19 has remained uncertain. Prior to the COVID-19 pandemic, the impact of statins in acute respiratory distress syndrome (ARDS) and sepsis was unclear (11) (12) (13) , with some trials showing no impact on mortality (14) (15) (16) , while others found a significant improvement (17) (18) (19) . Observational studies have similarly yielded mixed results regarding the effects of statins in COVID-19. These investigations have been limited by small sample size (20-23), insufficient adjustments for time varying confounders (20, 24, 25) , and lack of a sub-cohort newly initiated on statins for COVID-19 (24, (26) (27) (28) .

During Spring 2020, physicians at MGH created clinical guidelines that recommended starting statin therapy on patients hospitalized for severe COVID-19 with pre-existing primary indications (29, 30) . Clinicians were advised to continue pre-hospital statins and to start atorvastatin 40 mg daily on patients who had an evidence-based indication. Based upon the discretion and clinical judgement of the physician, many patients both with and without pre-existing cardiovascular disease, were started on statin therapy. This placed MGH in a unique position to investigate empirically the impact of starting patients on statin therapy during hospitalization due to A c c e p t e d M a n u s c r i p t 6 The aim of our study was to evaluate the effect of statins on 28-day time to death in patients hospitalized with COVID-19, using robust models to account for variable timing of statin initiation and competing risks. We further aimed to evaluate the specific effect of new statin initiation on survival.

This study utilizes a previously described cohort of patients hospitalized at MGH (31) . Inclusion criteria included > 18 years of age confirmed SARS-CoV-2 infection with reverse transcriptasepolymerase chain reaction testing, and hospitalization between March and June 2020. This study was approved by the local Institutional Review Board (IRB # 2020P000829); a waiver of informed consent was granted.

Following manual chart review, supplemented by medication orders automatically extracted from electronic health records, patients were categorized into four groups: (A) continued home statin during hospitalization ("continued"), (B) discontinued home statin during hospitalization ("discontinued"), (C) newly initiated statin during hospitalization ("newly initiated"), and (D) did not use statins during or prior to hospitalization ("never") [ Figure 1 ]. When manual chart review from the patient registry (30) was in conflict with the electronic medication order data, Z.N.M. resolved any conflicts with an additional round of manual chart reviews.

A c c e p t e d M a n u s c r i p t 7

Chart abstractors collected information on age, sex, smoking status, medical comorbidities, medications, and date of hospital admission, ICU admission, death, and discharge within 28 days of presentation to care. Laboratory values, self-reported race/ethnicity and body mass index (BMI) were extracted from the electronic health record.

The primary outcome was time to death. Patients discharged to palliative care were classified as deceased on the day of their discharge. The secondary outcome was time to ICU admission or death. For this outcome, a patient must have initiated statins during hospitalization but prior to ICU admission to be categorized as newly initiated or continued.

We examined differences between baseline characteristics among the four statin groups, reporting Fisher's exact test for categorical variables and Kruskal-Wallis test by ranks for continuous variables.

Analyses that stratify patients by in-hospital statin use are subject to both immortal time bias and time-varying confounding, as a patient's changing health condition affected when and whether they initiated statins (32) . Therefore, we used marginal structural Cox proportional hazards models to evaluate the effect of statins (33) . Patients discharged alive or transferred to a non-palliative care facility were categorized together as discharged. To fit the marginal structural Cox model, we fit a pooled multinomial regression to account for discharge as a competing risk, (34) and used inverse-probability weights that were stabilized and trimmed at the 5 th and 95 th percentiles. If patients did not experience the outcome and were not discharged by 28 days, they were administratively censored. We estimated the hazard ratio of each outcome for initiating statins vs. not initiating statins by the previous day.

The following baseline variables were included as confounders: demographic variables (sex, age>65 years, race, active smoker, BMI>30), comorbidities on admission (coronary artery disease, M a n u s c r i p t 8 congestive heart failure, hypertension, diabetes, dyslipidemia, chronic liver disease, active cancer, pulmonary disease), ACE inhibitor use at presentation to care, number of days from March 1 st , 2020 to the date of hospitalization to account for era effect, and prior statin usage. The following time-varying daily lab measurements were included and log-transformed: absolute lymphocyte count, white blood cell count (WBC), aspartate aminotransferase (AST), C-reactive protein (CRP), creatine kinase (CK) and alanine aminotransferase (ALT). To account for missing data, we used multiple imputation with 25

imputations. Peak lab values were calculated for each statin group, defined as the highest lab measurement observed between hospital admission to the end of follow-up.

For the primary outcome of mortality, we also adjusted for ICU admission status each day as a time-varying confounder. 95% confidence intervals and p-values were calculated, accounting for the uncertainty due to estimation of the weighting models (34) , and results across imputations were combined using Rubin's rules (35) .

The analysis was repeated for the primary and secondary outcomes on the subset of patients who were not prior users ("Newly initiated" vs. "Never") and patients who were prior users ("Continued" vs.

"Discontinued"). In total, six models were fit. All analyses were conducted in R Version 4.0.2 (36). The nnet package (37) was used to fit the multinomial regression model and the jomo package (38) was used to perform multiple imputation. A Benjamini-Hochberg correction was applied to control the false discovery rate (39) .

A c c e p t e d M a n u s c r i p t 9

An additional analysis was performed using E-values to assess robustness of the observed results to unmeasured confounding. The E-value assesses how strong an unmeasured confounder would have to be to fully explain away the observed results (40) . We also assessed whether the effect of statins differed in patients above and below 65 years of age. First, we fit the marginal structural models including an interaction term between statin initiation and whether a patient was over 65 years old, and then repeated the analysis, stratifying by whether patients were over 65. Finally, we assessed whether exclusion of patients who were admitted to the ICU on the same day of their hospital admission affected the relationship between statin initiation and the primary outcome of mortality.

Overall, 1179 adult patients with confirmed SARS-CoV-2 were included, after the exclusion of 7 patients who were deceased, discharged, or censored on the day of their hospital admission Table 1 ). 676 (57%) were male, 443 (38%) were at least 65 years old, and 493 (46%) had a BMI 30. Patient characteristics differed by statin group (Table 1) . Patients on statins prior to hospitalization (groups A and B) were older (median age 69 vs. 52 years, P < 0.001), and had higher rates of coronary artery disease (29% vs 3%, P < 0.001), congestive heart failure (19% vs. 5%, P < 0.001), hypertension (74% vs. 34%, P< 0.001), type 2 diabetes (56% vs. 17%, P < 0.001), and dyslipidemia (67% vs. 16%, P < 0.001) than those not on statins prior to hospitalization (groups C and D). White/non-Hispanics were more likely to be on statins prior to hospitalization than Hispanics (56% of White/non-Hispanics on statins vs. 33% of Hispanics on statins, P < 0.001).

In total, 777 patients (66%) received a statin during their hospitalization for COVID-19. 274/285 (96%) patients newly initiated statins and 331/434 (76%) patients continued on statins were prescribed atorvastatin. The most common dosage was atorvastatin 40mg daily. Among those continued on statins, A c c e p t e d M a n u s c r i p t 10 the majority were prescribed statins for more than a year prior to hospitalization (244/466, 52%). Table 2 contains information on when statins were initiated during hospitalization relative to admission date.

According to first laboratory measurements obtained during hospitalization, patients who discontinued statins at hospitalization had higher erythrocyte sedimentation rate (P = 0.046), CK (P = 0.001), troponin (P < 0.001), and D-dimer (P = 0.002) compared to the other cohorts (Table 1) .

In this cohort, 154 (13%) patients died and 841 (71%) were discharged within 28 days. In unadjusted analyses, patients on statins during hospitalization had similar rates of death (108 (14%) vs. 46 (11%), P = 0.273), but higher rates of ongoing hospitalization at 28 days (144 (19%) vs. 40 (10%), P< 0.001) and ICU admission (276 (36%) vs. 85 (21%), P < 0.001) than those not on statins during hospitalization ( Table 2) .

Unadjusted peak liver biochemistries and inflammatory markers differed across statin groups (Table 3) The median time to death in each statin group can be found in Table 1 (Figure 2) . A summary of the distribution of missing laboratory measurements can be found in Supplementary Table 3 .

198 patients were excluded from secondary outcome analyses because they were admitted to the ICU on their day of hospitalization (Supplementary Table 1 A c c e p t e d M a n u s c r i p t 12 When an interaction term between statin use and being over 65 years old was included in the model, the interaction term was observed to be statistically significant for the primary outcome when including all participants (HR 0.293, P=0.009) and newly initiated vs. never (HR 0.194, P=0.008), which indicated that statins were more protective among patients over 65 years of age (Supplementary Table   5 Table 7) .

When patients who were admitted to the ICU the same day as their hospital admission were excluded from analyses of the primary outcome, the protective effect of statins was preserved, whether or not analyses were restricted to patients who had statin usage prior to hospitalization (Supplementary Table 8 ).

In this large cohort from a single tertiary medical center, we found that statin use during hospitalization for COVID-19 was associated with reduced short-term mortality. The survival benefit was seen in both those who continued and those who newly initiated therapy while hospitalized. In sensitivity analyses, statin use was associated with reduced mortality for patients older than 65 years, but not 65 years old or younger. The protective association of statins against mortality was preserved even when patients who were admitted immediately to the ICU were excluded from the analysis. Our study confirms and expands on prior work. A recent propensity score-matched analysis found that statin use prior to hospitalization reduces the risk of short-term in-hospital mortality from COVID-19 (27) . This study probed further, into whether in-hospital statin use had a similar effect on mortality. To investigate the impact of statins administered during hospitalization, we used marginal structural models, which account for both survivorship bias (i.e., patients need to survive long enough to begin statins) and time-varying confounding bias (i.e., patient health status during hospitalization changes over time, affecting the likelihood of initiating treatment). Our study accounted for a wide variety of time-varying confounders, which we believe accurately captures temporal shifts in the likelihood of initiating treatment. We further expanded on prior literature by specifically evaluating the effect of statin initiation during hospitalization without prior use, because 26% of our cohort was newly initiated on statins during COVID-19 hospitalization. Overall, the novel findings presented here are that statin therapy during hospitalization, whether it be a new or continued prescription, was associated with reduced mortality.

The composition of our cohort was similar to other published patient databases of patients with COVID-19 (21, 26, 28). The median age of patients was 60 years old (IQR 47-73 years). Obese patients with a BMI 30 represented almost half the population (46%), a similar rate to prior studies (21, 26, 41) and consistent with evidence that obesity is a risk factor for hospitalization with COVID-19 (42) . Racial and ethnic demographics vary immensely across the literature. However, it is important to note that nationwide, large observational studies have illustrated that underserved communities and people of color are more likely to be hospitalized for COVID-19 (43) . This study re-enforces these findings, with the majority of patients identifying with a race or ethnicity other than Caucasian (61%), with Hispanic patients (36.4%) being the most common, followed by Asian and Native American patients (13%), and Black/Non-Hispanic patients (10.8%). This cohort's mortality rate (13.1%) was similar to the mean published United States hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic (11.8%) among 955 hospitals (44) .

A c c e p t e d M a n u s c r i p t 14 Our findings contradict some prior reports. One meta-analysis of 3,449 patients in 9 observational studies found that statin use did not improve severe outcomes or mortality in COVID-19 (45) . The majority of these studies were small in size (as few as 50 patients) and most failed to control for potential confounders. Comorbidities such as diabetes, cardiovascular disease and obesity are established risk factors for more severe COVID-19 disease, and patients prescribed statins are more likely to have these comorbidities, highlighting the critical need to control for confounding in this analysis (22) . Additionally, most prior work either examined the relationship with antecedent statin usage prior to hospitalization (23, (25) (26) (27) (28) or exclusively during hospitalization (20, 22, 24) . Our study had several advantages: we investigated the influence of statin use both prior to and during hospitalization, minimized immortal time bias, adjusted for time-varying confounders, and minimized era effect (or the potential changes in COVID-19 care over time). These advantages provide clarity not offered by previous studies.

The duration of statin therapy required to provide mortality benefit in COVID-19 remains unclear. This study suggests that statins do not cause harm and may be associated with a survival benefit even after brief exposure during hospitalization. The reduced hazard of death associated with statin usage was greatest in patients continued on statin therapy, suggesting that the benefit seen with statin exposure may be greater with longer exposure to statins prior to illness. It is important to note that while patients newly started on statins were found to have an associated mortality benefit, this cohort was also found to have higher levels of ICU admission compared to patients continued on antecedent statin usage. As table 1 illustrates, patients newly initiated on statins were found to have higher levels of inflammatory markers compared to the antecedent statin usage group, CRP (85, ), ESR (49 (35-84) ), and D-dimer (1554 (826-6580)). While our data does not prove this, it is theoretically possible that statin usage prior to viral infection may blunt the inflammatory response caused by both the virus and the immune system. For instance, in a prior phase-2 randomized, placebo-controlled, multicenter trial investigating the impact of atorvastatin on severe sepsis, the investigators found that prior statin use decreased interleukin-6 levels and reduced mortality, however, this was not seen in statin naïve patients receiving in-hospital statin A c c e p t e d M a n u s c r i p t 15 exposure only (11) . Further insight is needed on a possible dose and duration effect. Interestingly, in a recent Cochrane systematic review that assessed the effects of early administered statins on patients with acute coronary syndrome, they found no significant reduced risk of death, non-fatal myocardial ischemia or stroke at 1 month (46) . Further study is needed on the main therapeutic mechanism of action of statins on patients infected with SARS-COV-2 and how this may differ from the benefits seen in cardiovascular disease. Given the association between COVID-19 infection and a hyperinflammatory response that provokes end organ damage (6), it is possible that new initiation of statins even for a short duration could have provided a positive impact on both mortality and secondary complications.

Another proposed explanation for statins' mechanism of action in COVID-19 is the drug's ability to inhibit hydroxymethylglutaryl-coenzyme A reductase, which may interfere with the virus' invasion into cells by compromising the lipid-rich membrane required for SARS-CoV-2 to interact with the cellular receptor angiotensin-converting enzyme 2 (47) . If statins improve COVID-19 outcomes by inhibiting viral cell invasion, the benefit may be enhanced when statins are prescribed before infection.

In this study, we found an association with mortality benefit with statin use in adults over 65 years old but not in patients 65 years or younger. Given these findings were generated from a sensitivity analysis, we hesitate to provide age cut-offs for statin initiation for the treatment of COVID-19, but do not believe that age should be a contraindication to statin use during COVID-19 hospitalization.

Liver biochemistries are frequently elevated in severe COVID-19 disease and are associated with worse clinical outcomes (48) . Separately, statins are known to increase liver biochemistries in certain patients (42) . In our study, newly initiated statin use was associated with higher levels of peak AST and ALT throughout hospitalization; however, only 16% of patients on statins developed an ALT level greater than 5 times the upper limit of normal, which is a similar rate compared other cohorts with severe COVID (49) . These findings are limited in that peak levels could have occurred before or after statin initiation and A c c e p t e d M a n u s c r i p t 16 were unadjusted for confounding. Despite these limitations, there is no clear evidence that statin exposure during infection is associated with clinically important hepatotoxicity.

Myotoxicity is a known, albeit rare, complication of statins. In the context of COVID-19, where creatinine kinase elevations are prevalent, there is concern that statins could increase myotoxicity and subsequent creatinine kinase-induced nephrotoxicity. This was not seen among individuals newly initiated on statins or continued on statin therapy, with creatinine kinase peak levels never reaching three times the upper limit of normal, considered the threshold for acute kidney injury due to pigment associated nephropathy (50) .

Our findings must be interpreted in the context of study design. Although we utilized two data sources to confirm demographics, medications, laboratory data and clinical outcomes, misclassification errors are possible. We limited this error rate by employing physician review of discrepant data.

Additionally, we were unable to account for patients who had dose escalations in their statin usage or who had their statin temporarily held during hospitalization. Finally, patients who were on statin therapy prior to hospitalization but had the medication discontinued during hospitalization, presumably due to organ dysfunction, are a unique sub-cohort of patients that warrant further exploration, and there may be M a n u s c r i p t 29 Figure 1 A c c e p t e d M a n u s c r i p t 30 Figure 2 

United States COVID-19 Cases and Deaths by State

Department of Health & Human Services

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

COVID-19 and Cardiovascular Disease

The Variety of Cardiovascular Presentations of COVID-19

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection

Epub 2020/06/05

National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey

Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial

Statins: a viable candidate for host-directed therapy against infectious diseases

Statins and the COVID-19 main protease

A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis

Statins for sepsis: a critical and updated review

Statins in community acquired pneumonia: Evidence from experimental and clinical studies

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

Simvastatin in the acute respiratory distress syndrome

Statin therapy and mortality from sepsis: a meta-analysis of randomized trials

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

Association between use of statins and mortality among patients hospitalized with laboratoryconfirmed influenza virus infections: a multistate study

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients

Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study

Statin use is associated with lower disease severity in COVID-19 infection

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients

PubMed Central PMCID: PMC7722358. 29. Hospital MG. Rationale for Consideration of Statins for COVID-19 Patients: The General Hospital Corporation

Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system

Massachusetts general hospital Covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity

Statistical Analysis of Clinical COVID-19 Data: A Concise Overview of Lessons Learned, Common Errors and How to Avoid Them

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men

A marginal structural model for multiple-outcome survival data:assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort

University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (afternoon panel session)

R Foundation for Statistical Computing

Modern Applied Statistics with S

Jomo: a flexible package for two-level joint modelling multiple imputation

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Sensitivity Analysis Without Assumptions

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Independent Role of Severe Obesity as a Risk Factor for COVID-19 Hospitalization: A Spanish Population-Based Cohort Study. Obesity (Silver Spring)

The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States

Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic

Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection

Statins for acute coronary syndrome

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Liver Injury as a Surrogate for Inflammation and Predictor of Outcomes in COVID-19

Clinical Features of COVID-19 Related Liver Damage

Clinical profile and outcome of pigment-induced nephropathy

Alaska Native, Asian, Native Hawaiian, Pacific Islander, others)

A c c e p t e d M a n u s c r i p t 27 A c c e p t e d M a n u s c r i p t 28